Generation of highly purified human cardiomyocytes from peripheral blood mononuclear cell-derived induced pluripotent stem cells

Induced pluripotent stem (iPS) cells have an enormous potential for physiological studies. A novel protocol was developed combining the derivation of iPS from peripheral blood with an optimized directed differentiation to cardiomyocytes and a subsequent metabolic selection. The human iPS cells were...

Full description

Saved in:
Bibliographic Details
Published in:PloS one Vol. 10; no. 5; p. e0126596
Main Authors: Fuerstenau-Sharp, Maya, Zimmermann, Martina E, Stark, Klaus, Jentsch, Nico, Klingenstein, Melanie, Drzymalski, Marzena, Wagner, Stefan, Maier, Lars S, Hehr, Ute, Baessler, Andrea, Fischer, Marcus, Hengstenberg, Christian
Format: Journal Article
Language:English
Published: United States Public Library of Science 13-05-2015
Public Library of Science (PLoS)
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Induced pluripotent stem (iPS) cells have an enormous potential for physiological studies. A novel protocol was developed combining the derivation of iPS from peripheral blood with an optimized directed differentiation to cardiomyocytes and a subsequent metabolic selection. The human iPS cells were retrovirally dedifferentiated from activated T cells. The subsequent optimized directed differentiation protocol yielded 30-45% cardiomyocytes at day 16 of differentiation. The derived cardiomyocytes expressed appropriate structural markers like cardiac troponin T, α-actinin and myosin light chain 2 (MLC2V). In a subsequent metabolic selection with lactate, the cardiomyocytes content could be increased to more than 90%. Loss of cardiomyocytes during metabolic selection were less than 50%, whereas alternative surface antibody-based selection procedures resulted in loss of up to 80% of cardiomyocytes. Electrophysiological characterization confirmed the typical cardiac features and the presence of ventricular, atrial and nodal-like action potentials within the derived cardiomyocyte population. Our combined and optimized protocol is highly robust and applicable for scalable cardiac differentiation. It provides a simple and cost-efficient method without expensive equipment for generating large numbers of highly purified, functional cardiomyocytes. It will further enhance the applicability of iPS cell-derived cardiomyocytes for disease modeling, drug discovery, and regenerative medicine.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Conceived and designed the experiments: MFS MEZ KS SW CH. Performed the experiments: MFS MEZ NJ MK MD SW. Analyzed the data: MFS MEZ NJ MD SW. Contributed reagents/materials/analysis tools: KS LSM UH AB MF CH. Wrote the paper: MFS MEZ SW CH.
Competing Interests: The authors have declared that no competing interests exist.
These authors also contributed equally to this work.
Current address: Department of Genetic Epidemiology, Institute of Epidemiology and Preventive Medicine, University of Regensburg, Regensburg, Germany
Current address: Sartorius Stedim Biotech GmbH, R&D Cell Culture Technologies, Göttingen, Germany
Current address: DZHK (German Centre for Cardiovascular Research), partnersite Munich Heart Alliance, Munich, Germany
Current address: Deutsches Herzzentrum München, Technische Universität München, Munich, Germany
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0126596